Scaling-up a lateral flow assay for routine manufacture is a critical phase in realising the commercial ambitions for an assay. It is at this stage where an assay is taken through a series of validation and optimisation steps. In the latest of the Abingdon Health Nanos, Technical Transfer Manager, Jon Flint discusses 3 key considerations for scaling-up a lateral flow assay for routine manufacture.
The transcript for the video, ‘3 key considerations for scaling-up a lateral flow assay to routine manufacture’.
"Lateral flow assays are quite a mix of lots of different components and they all feed into one another. So, ensuring the materials, particularly the reagents, set to you in development are the appropriate ones, they’re plentiful, they’re accessible and they’re robust and they’re suitable for use on the [lateral flow] manufacturing equipment.”
“One of the key elements is making sure that the design freeze has been achieved. It seems obvious, but you need to make that the assay is fully optimised to give it the best possible chance before we take it to scale-up. To help with that we make sure the Tech Transfer Team is involved with the development work in that process.”
“Another key element is our experience and expertise. It’s really important, critical in fact, to have that knowledge have how your equipment works and how you can transfer materials using that equipment and the limitations and capabilities when doing the transfer process.”
To learn more about how Abingdon Health could be your lateral flow manufacturing partner please contact us on +44 (0) 1904 406082 or email email@example.com.